reference/25137828

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/25137828

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	2135
issn	1557-3265 1078-0432
issueIdentifier	7
pageRange	2128-2135
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	2128
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_06aba5a94448c92faf09747c7e7c67bd
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_4a5f466b044caa89eb4355829c9f4ac6
bibliographicCitation	Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Jiao Q, Prabhakar U, Lang Z, Corringham RE, Beckman RA, Jayson GC. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res. 2007 Apr 01;13(7):2128–35. doi: 10.1158/1078-0432.ccr-06-2779. PMID: 17404096.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d9b94a10b99fd16faec447c8dba6caf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6c67a422cca97d13123c40ae48d35157 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8fb2cc703427fa668f4b7822a528781a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1cd3035962f3236516fcd79c67858c6a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e2991078a72f7711de9c7b8abafa48cd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6cc4593ae8fd6e92d7a97ee2a5c9bd90 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_da9c9a9e7a6e6c8183ed0e6786728104 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4234e5e8f4ab694f5cd4cac4a7dbbfa4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d721f10175c3d88779802b55f045e2c6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_28983fea8a1ccf04002e1e002a73624d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a90bee5eea5348f5dfb15e054f16b47 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c69fd89434d491c2b778342ee8770c59 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8b720d3cadeaf021813c24d3c941d09 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27ced2b0d2f09c29944e9d5dae9e8da2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_179ddb98d70a83b26d29b190ab800478 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b312196bb1858d977f5371a0ee14dc4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_61bd798dadfb76aaf20472d7ae3e1155 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_792ff3ea9a626704a311e3229470b972 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ef8e3732de443d918cba26231d4f126e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f68f77091da8f429bcb4e86531dac7cc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_20457e1ce13ee91950dadab639c8fa54 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d4f8761fd78d24220d559ed44ec01760 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9a5557863f981fa02b3ee9a6b7c674ef http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e6385cb7f2d49385f693f037bc145f9e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9b96616837d67aaf6539ee3340e0b0d6
date	2007-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/17404096 https://doi.org/10.1158/1078-0432.ccr-06-2779
isPartOf	https://portal.issn.org/resource/ISSN/1078-0432 https://portal.issn.org/resource/ISSN/1557-3265 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors
discusses	http://id.nlm.nih.gov/mesh/M0230139 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0001357
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000911Q000009 http://id.nlm.nih.gov/mesh/D009369Q000188 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D000970Q000493 http://id.nlm.nih.gov/mesh/D000911Q000493 http://id.nlm.nih.gov/mesh/D039564Q000378
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D007150 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D049268 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D039564Q000276 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D020714 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008279
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_4f3366af2ce1555e259faab86aad3bef http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_bf22a1d0acfca4af517e1417a80e92d1 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7156 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_a81b4e81fe71a07613c76a5538fe8b5e http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7942 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1983 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7732 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_a73b4feef7226074b49b42d83fadea5b

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID243214637 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129205537

Total number of triples: 79.